A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Indiana University
Study ID
NCT00393497
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    Bevacizumab 15 mg/kg IV every 21 days

Study Details

The purpose of this study is to evaluate the effectiveness of bevacizumab in women with lymphedema as a result of previous treatment for breast cancer.

Key Dates

First listed
Oct 27, 2006
Start date
Apr 30, 2007
Status verified
Sep 2014
Primary completion
Oct 31, 2009
Completion
Jan 31, 2011

Study Design

Enrollment
11 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Arm Volume [ Time Frame: baseline, Day 1, Day 22, q 6wks, termination ]

Locations (1)

FacilityCityStateZIPSite coordinators
Indiana University Cancer CenterIndianapolisIndiana46202-

Find similar trials in Indianapolis, IN

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Indiana University Cancer Center· Indianapolis, IN

Related Studies